List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3501831/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transcriptomic changes during stage progression of mycosis fungoides. British Journal of Dermatology, 2022, 186, 520-531.	1.5	4
2	Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors. Blood Advances, 2022, 6, 2334-2345.	5.2	7
3	Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma. Cells, 2022, 11, 593.	4.1	6
4	Case Report: Chemotherapy-Associated Systemic Sclerosis: Is DNA Damage to Blame?. Frontiers in Medicine, 2022, 9, 855740.	2.6	3
5	Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 797-806.	2.4	36
6	Population-Based Study Detailing Cutaneous Melanoma Incidence and Mortality Trends in Canada. Frontiers in Medicine, 2022, 9, 830254.	2.6	13
7	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. Dermatology and Therapy, 2022, 12, 253-265.	3.0	2
8	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy, 2022, 12, 1073-1089.	3.0	1
9	Analysis of Geographic and Environmental Factors and Their Association with Cutaneous Melanoma Incidence in Canada. Dermatology, 2022, 238, 1006-1017.	2.1	6
10	Genomic instability in early systemic sclerosis. Journal of Autoimmunity, 2022, 131, 102847.	6.5	9
11	Diagnosis of gamma/delta mycosis fungoides requires longitudinal clinical observation. Journal of the American Academy of Dermatology, 2021, 85, 1352-1353.	1.2	3
12	Clinical Outcomes Among Bullous Pemphigoid Patients—A Comparison of Urban and Rural Populations. Journal of Cutaneous Medicine and Surgery, 2021, 25, 150-156.	1.2	0
13	Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management. Journal of Cutaneous Medicine and Surgery, 2021, 25, 59-76.	1.2	90
14	Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective realâ€world evidence study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e341-e343.	2.4	16
15	European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 27-49.	2.4	28
16	Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome. Dermatology, 2021, 237, 479-485.	2.1	5
17	Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 797-806.	2.4	6
18	R _x IALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study. BMI Open, 2021, 11, e043612.	1.9	6

#	Article	IF	CITATIONS
19	The ecological approach to biologic drugs: survival of the fittest. British Journal of Dermatology, 2021, 184, 996-997.	1.5	1
20	Psoriasis Prevalence and Severity by Expert Elicitation. Dermatology and Therapy, 2021, 11, 1053-1064.	3.0	28
21	Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. Cancers, 2021, 13, 2282.	3.7	6
22	Patterns of Gene Expression in Cutaneous T-Cell Lymphoma: Systematic Review of Transcriptomic Studies in Mycosis Fungoides. Cells, 2021, 10, 1409.	4.1	4
23	Nailfold Capillaroscopy Abnormalities Correlate With Disease Activity in Adult Dermatomyositis. Frontiers in Medicine, 2021, 8, 708432.	2.6	8
24	Reflex Molecular Testing in Melanoma Diagnosis: When Should BRAF Mutation Testing Be Ordered and Who Should Order It?. Journal of Cutaneous Medicine and Surgery, 2021, , 120347542110453.	1.2	1
25	27764 Muffin technique micrographic surgery for nonmelanoma skin cancer. Journal of the American Academy of Dermatology, 2021, 85, AB39.	1.2	Ο
26	The Clinical Spectrum of Primary Cutaneous CD4+ Small/Medium-Sized Pleomorphic T-Cell Lymphoproliferative Disorder: An Updated Systematic Literature Review and Case Series. Dermatology, 2021, 237, 618-628.	2.1	14
27	Intertriginous Mycosis Fungoides with T Follicular Helper Cell Phenotype progressing to Sézary Syndrome. Clinical and Experimental Dermatology, 2021, , .	1.3	1
28	Gene Expression Profiling of Mycosis Fungoides in Early and Tumor Stage—A Proof-of-Concept Study Using Laser Capture/Single Cell Microdissection and NanoString Analysis. Cells, 2021, 10, 3190.	4.1	1
29	Biomarkers of B cell activation in autoimmune connective tissue diseases: More than markers of disease activity. Clinical Biochemistry, 2021, 100, 1-1.	1.9	2
30	Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis. Journal of Rheumatology, 2020, 47, 59-65.	2.0	39
31	Use of Extracorporeal Photopheresis in Scleroderma: A Review. Dermatology, 2020, 236, 105-110.	2.1	12
32	Overall Survival in Mycosis Fungoides: AÂSystematicÂReview and Meta-Analysis. Journal of Investigative Dermatology, 2020, 140, 495-497.e5.	0.7	43
33	Predicting the longâ€ŧerm outcomes of biologics in patients with psoriasis using machine learning. British Journal of Dermatology, 2020, 182, 1305-1307.	1.5	30
34	Oral and Intraincisional Antibiotic Prophylaxis in Mohs Surgery: A Systematic Review and Meta-analysis. Dermatologic Surgery, 2020, 46, 558-560.	0.8	12
35	European dermatology forum – updated guidelines on the use of extracorporeal photopheresis 2020 – part 1. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2693-2716. 	2.4	49
36	The Neoantigen Landscape of Mycosis Fungoides. Frontiers in Immunology, 2020, 11, 561234.	4.8	6

#	Article	IF	CITATIONS
37	16079 Alternate data presentation models in psoriasis: Exploring individualized approaches. Journal of the American Academy of Dermatology, 2020, 83, AB170.	1.2	0
38	Diagnostic challenge of aleukemic leukemia cutis preceding acute myelogenous leukemia: A case report. SAGE Open Medical Case Reports, 2020, 8, 2050313X2091963.	0.3	4
39	Independent evolution of cutaneous lymphoma subclones in different microenvironments of the skin. Scientific Reports, 2020, 10, 15483.	3.3	3
40	Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis. Dermatologic Therapy, 2020, 33, e14258.	1.7	2
41	913 A variant of Mohs micrographic surgery: The muffin technique. Journal of Investigative Dermatology, 2020, 140, S120.	0.7	0
42	Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma. Blood Advances, 2020, 4, 2489-2500.	5.2	45
43	Review of Machine Learning in Predicting Dermatological Outcomes. Frontiers in Medicine, 2020, 7, 266.	2.6	23
44	507 Alternative data presentation methods: Exploring waterfall and bubble plots in psoriasis biologic clinical trials. Journal of Investigative Dermatology, 2020, 140, S69.	0.7	0
45	Artificial Intelligence Applications in Dermatology: Where Do We Stand?. Frontiers in Medicine, 2020, 7, 100.	2.6	78
46	Muffin Technique Micrographic Surgery for Non-melanoma Skin Cancer. Frontiers in Medicine, 2020, 7, 637223.	2.6	2
47	Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative Meta-Analysis. Frontiers in Medicine, 2020, 7, 625755.	2.6	23
48	Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. Journal of the American Academy of Dermatology, 2019, 80, 60-69.e2.	1.2	126
49	How I learned to stop worrying about antidrug antibodies. British Journal of Dermatology, 2019, 182, 19-20.	1.5	0
50	A case of progressive lower leg edema. JAAD Case Reports, 2019, 5, 621-623.	0.8	1
51	Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. Journal of Cutaneous Medicine and Surgery, 2019, 23, 537-544.	1.2	18
52	High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach. Journal of Infectious Diseases, 2019, 220, 1312-1324.	4.0	13
53	Skin Patterning in Psoriasis by Spatial Interactions between Pathogenic Cytokines. IScience, 2019, 20, 546-553.	4.1	11
54	Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis. Dermatologic Therapy, 2019, 32, e12846.	1.7	7

#	Article	IF	CITATIONS
55	114 Cutaneous T-Cell lymphoma is genetically and clonotypically heterogeneous. Journal of Investigative Dermatology, 2019, 139, S20.	0.7	0
56	Macular cutaneous amyloidosis treated with methyl aminolevulinate and daylight photodynamic therapy: A case report. SAGE Open Medical Case Reports, 2019, 7, 2050313X1982961.	0.3	1
57	Factors predicting persistence of biologic drugs in psoriasis: a systematic review and metaâ€analysis. British Journal of Dermatology, 2019, 181, 450-458.	1.5	71
58	Clonotypic Diversity of the T-cell Receptor Corroborates the Immature Precursor Origin of Cutaneous T-cell Lymphoma. Clinical Cancer Research, 2019, 25, 3104-3114.	7.0	36
59	Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma. Blood, 2019, 134, 1517-1527.	1.4	44
60	Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing. Blood Advances, 2019, 3, 1175-1184.	5.2	39
61	Prescribing Home Narrowband UVB Phototherapy: A Review of Current Approaches. Journal of Cutaneous Medicine and Surgery, 2019, 23, 91-96.	1.2	9
62	Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome. Oncotarget, 2019, 10, 4894-4906.	1.8	3
63	Differentiating malignant melanoma from other lesions using dermoscopy. Canadian Family Physician, 2019, 65, 412-414.	0.4	4
64	Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a populationâ€based followâ€up study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2185-2190.	2.4	12
65	Risk of skin cancer in patients with HIV: A Danish nationwide cohort study. Journal of the American Academy of Dermatology, 2018, 79, 689-695.	1.2	54
66	生物å^¶å‰,和生物仿å^¶è•å⁻¹ä¸åº¦è‡³é‡åº¦æ−'å⊷状鑑¶å±'ç−…æ,£è€…的安全性ã€ç−−æ•	`å 'Œē ç‰(©åðæ´»çŽ‡. Bi
67	Longâ€ŧerm optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1297-1304.	2.4	12
68	Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics Journal, 2018, 18, 494-500.	2.0	51
69	Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2018, 178, 509-519.	1.5	239
70	PO-044 Possible involvement of G2/M block defects in cell sensitivity towards ATR inhibitors. ESMO Open, 2018, 3, A37.	4.5	0
71	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section IV: Treatment Options for the Management of Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2018, 22, 21S-29S.	1.2	17
72	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2018, 22, 30S-35S.	1.2	9

#	Article	IF	CITATIONS
73	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Journal of Cutaneous Medicine and Surgery, 2018, 22, 3S-5S.	1.2	5
74	Using target capture based high throughput DNA sequencing methodology to identify T-cell receptor sequences in mycosis fungoides. European Journal of Cancer, 2018, 101, S3.	2.8	0
75	TOX expression in patients with Mycosis fungoides- a potential diagnostic marker?. European Journal of Cancer, 2018, 101, S9.	2.8	0
76	Identifying intratumor heterogeneity in mycosis fungoides using high throughput DNA sequencing. European Journal of Cancer, 2018, 101, S2-S3.	2.8	0
77	Single-cell heterogeneity in Sézary syndrome. Blood Advances, 2018, 2, 2115-2126.	5.2	78
78	LB1479 Identifying intratumor heterogeneity in mycosis fungoides using high throughput DNA sequencing. Journal of Investigative Dermatology, 2018, 138, B2.	0.7	0
79	CCR4-targeted therapy in cutaneous T-cell lymphoma. Lancet Oncology, The, 2018, 19, 1140-1141.	10.7	10
80	Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. PLoS ONE, 2018, 13, e0192010.	2.5	34
81	Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma. Leukemia and Lymphoma, 2017, 58, 171-178.	1.3	5
82	Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderateâ€toâ€severe plaque psoriasis – nationwide results from the <scp>DERMBIO</scp> registry. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1183-1187.	2.4	21
83	Psoralen with ultraviolet Aâ€induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1–STAT1 pathway. Photodermatology Photoimmunology and Photomedicine, 2017, 33, 164-171.	1.5	13
84	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. European Journal of Cancer, 2017, 77, 57-74.	2.8	363
85	High diversity of the T-cell receptor repertoire of tumor-infiltrating lymphocytes in basal cell carcinoma. Experimental Dermatology, 2017, 26, 454-456.	2.9	8
86	Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study. Dermatologic Therapy, 2017, 30, e12550.	1.7	34
87	Folliculotropism Does Not Affect Overall Survival in Mycosis Fungoides: Results from a Single-Center Cohort and Meta-Analysis. Dermatology, 2017, 233, 320-325.	2.1	4
88	726 The cytokine expression profile of mycosis fungoides and Sezary Syndrome cells after psoralen with UVA treatment. Journal of Investigative Dermatology, 2017, 137, S125.	0.7	0
89	Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study. Journal of the American Academy of Dermatology, 2017, 77, 719-727.	1.2	34
90	Ubiquitin-specific peptidase 2 as a potential link between microRNA-125b and psoriasis. British Journal of Dermatology, 2017, 176, 723-731.	1.5	17

#	Article	IF	CITATIONS
91	A randomized, doubleâ€blind, placeboâ€controlled, doseâ€escalation firstâ€inâ€man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, <scp>AVX</scp> 001, in patients with mild to moderate plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1161-1167.	2.4	28
92	Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin. BMC Cancer, 2017, 17, 675.	2.6	45
93	Primary cutaneous lymphomas – diagnostic and therapeutic guidelines of the Polish Dermatological Society. Przeglad Dermatologiczny, 2017, 3, 243-268.	0.1	2
94	Immunosuppressive Environment in Basal Cell Carcinoma: The Role of Regulatory T Cells. Acta Dermato-Venereologica, 2016, 96, 917-921.	1.3	50
95	TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides. Frontiers in Medicine, 2016, 3, 51.	2.6	11
96	Imaging of cutaneous Tâ€cell lymphomas by optical coherence tomography – a case series study. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1228-1229.	2.4	2
97	The role of cytokine deficiencies and cytokine autoantibodies in clinical dermatology. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 404-412.	2.4	2
98	Patient Adherence to Biologic Agents in Psoriasis. Dermatology, 2016, 232, 326-333.	2.1	27
99	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood, 2016, 127, 1287-1296.	1.4	86
100	Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation. Journal of Dermatological Science, 2016, 84, 239-247.	1.9	16
101	Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology. Experimental Dermatology, 2016, 25, 839-846.	2.9	63
102	Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study. British Journal of Dermatology, 2016, 174, 1145-1146.	1.5	28
103	STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides. Clinical Cancer Research, 2016, 22, 3328-3339.	7.0	36
104	Patient-relevant needs and treatment goals in nail psoriasis. Quality of Life Research, 2016, 25, 1179-1188.	3.1	16
105	Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients. JAMA Dermatology, 2016, 152, 177.	4.1	73
106	Pigmentary Markers in Danes – Associations with Quantitative Skin Colour, Nevi Count, Familial Atypical Multiple-Mole, and Melanoma Syndrome. PLoS ONE, 2016, 11, e0150381.	2.5	5
107	Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma. Oncotarget, 2016, 7, 48391-48400.	1.8	16
108	Investigation of Human Cancers for Retrovirus by Low-Stringency Target Enrichment and High-Throughput Sequencing. Scientific Reports, 2015, 5, 13201.	3.3	34

ROBERT GNIADECKI

#	Article	IF	CITATIONS
109	IgM-type epidermolysis bullosa acquisita. British Journal of Dermatology, 2015, 173, 1566-1568.	1.5	9
110	Next-generation antipsoriatic drugs: small molecules join. British Journal of Dermatology, 2015, 173, 1355-1356.	1.5	2
111	Treatment of primary cutaneous anaplastic large cell lymphoma with superficial X-rays. Dermatology Reports, 2015, 7, 5888.	0.8	2
112	Low-Dose (10-Gy) Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma: An Open Clinical Study and Pooled Data Analysis. International Journal of Radiation Oncology Biology Physics, 2015, 92, 138-143.	0.8	64
113	Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls. Journal of Investigative Dermatology, 2015, 135, 1-5.	0.7	79
114	Delay in the Histopathologic Diagnosis of Mycosis Fungoides. Acta Dermato-Venereologica, 2015, 95, 472-475.	1.3	16
115	Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?. Clinics in Dermatology, 2015, 33, 456-461.	1.6	44
116	The Successful Use of Extracorporeal Photopheresis in a 12‥earâ€Old Patient with Refractory Epidermolysis Bullosa Acquisita. Pediatric Dermatology, 2015, 32, e60-1.	0.9	8
117	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of Clinical Oncology, 2015, 33, 3766-3773.	1.6	328
118	Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage. Leukemia and Lymphoma, 2015, 56, 739-747.	1.3	9
119	Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. British Journal of Dermatology, 2015, 172, 244-252.	1.5	239
120	Cardiovascular outcomes and systemic antiâ€inflammatory drugs in patients with severe psoriasis: 5â€year followâ€up of a Danish nationwide cohort. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1128-1134.	2.4	164
121	Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. Oncotarget, 2015, 6, 20555-20569.	1.8	78
122	Favourable results of Mohs micrographic surgery for basal cell carcinoma. Danish Medical Journal, 2015, 62, A5171.	0.5	8
123	IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF). Cell Cycle, 2014, 13, 1306-1312.	2.6	27
124	Implementing Best Practice in Psoriasis: A Nordic Expert Group Consensus. Acta Dermato-Venereologica, 2014, 94, 547-552.	1.3	13
125	Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas. Leukemia and Lymphoma, 2014, 55, 957-958.	1.3	28
126	Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. British Journal of Dermatology, 2014, 170, 591-598.	1.5	51

#	Article	IF	CITATIONS
127	The importance of Notch signaling in peripheral T-cell lymphomas. Leukemia and Lymphoma, 2014, 55, 639-644.	1.3	17
128	Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood, 2014, 124, 761-770.	1.4	59
129	Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment. BMC Dermatology, 2014, 14, 14.	2.1	10
130	miR-125b induces cellular senescence in malignant melanoma. BMC Dermatology, 2014, 14, 8.	2.1	45
131	Guidelines on the use of extracorporeal photopheresis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1-37.	2.4	212
132	Micro <scp>RNA</scp> expression analysis and <scp>M</scp> ultiplex ligationâ€dependent probe amplification in metastatic and nonâ€metastatic uveal melanoma. Acta Ophthalmologica, 2014, 92, 541-549.	1.1	29
133	Epigenetic Silencing of Mir-203 Contributes to IL2Rb Overexpression and Malignant Transformation in Cutaneous T-Cell Lymphoma. Blood, 2014, 124, 3553-3553.	1.4	3
134	Essential factors influencing health-related-quality of life in psoriasis. Journal of Drugs in Dermatology, 2014, 13, 246-50.	0.8	5
135	STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Research, 2014, 34, 5277-86.	1.1	15
136	MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Research, 2014, 34, 7207-17.	1.1	55
137	MicroRNAs in the pathogenesis of malignant melanoma. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 142-150.	2.4	28
138	Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma. British Journal of Dermatology, 2013, 168, 504-512.	1.5	14
139	Ultraviolet A1 phototherapy for mycosis fungoides. Clinical and Experimental Dermatology, 2013, 38, 126-130.	1.3	26
140	Cardiovascular disease event rates in patients with severe psoriasis treated with systemic antiâ€inflammatory drugs: a <scp>D</scp> anish realâ€world cohort study. Journal of Internal Medicine, 2013, 273, 197-204.	6.0	155
141	Treatment Patterns, Treatment Satisfaction, Severity of Disease Problems, and Quality of Life in Patients with Psoriasis in Three Nordic Countries. Acta Dermato-Venereologica, 2013, 93, 442-445.	1.3	33
142	Expression of miRâ€155 and miRâ€126 <i>in situ</i> in cutaneous Tâ€cell lymphoma. Apmis, 2013, 121, 1020-1	02240	25
143	STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle, 2013, 12, 1939-1947.	2.6	123
144	cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas. PLoS ONE, 2013, 8, e59390.	2.5	46

#	Article	IF	CITATIONS
145	Dose-creep of Infliximab During Psoriasis Treatment: An Observational Study. Acta Dermato-Venereologica, 2012, 92, 355-357.	1.3	17
146	MDM2 Inhibitor Nutlin-3a Induces Apoptosis and Senescence in Cutaneous T-Cell Lymphoma: Role of p53. Journal of Investigative Dermatology, 2012, 132, 1487-1496.	0.7	37
147	Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. Annals of Internal Medicine, 2012, 157, 846.	3.9	349
148	Effects of Anti–Tumor Necrosis Factor Therapy on Body Composition and Insulin Sensitivity in Patients With Psoriasis. Archives of Dermatology, 2012, 148, 1089.	1.4	20
149	PSS26 Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): An Integrated Approach of Outcomes Measurement in Nail Psoriasis. Value in Health, 2012, 15, A573.	0.3	0
150	Integrated Positron-Emission Tomography and Computed Tomography Manifestations of Cutaneous T-Cell Lymphoma. Archives of Dermatology, 2012, 148, 1420.	1.4	2
151	miR-122 Regulates p53/Akt Signalling and the Chemotherapy-Induced Apoptosis in Cutaneous T-Cell Lymphoma. PLoS ONE, 2012, 7, e29541.	2.5	99
152	Selfâ€reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1436-1443.	2.4	56
153	Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. British Journal of Dermatology, 2012, 166, 399-404.	1.5	40
154	Topical nutlinâ€3a does not decrease photocarcinogenesis induced by simulated solar radiation in hairless mice. Photodermatology Photoimmunology and Photomedicine, 2012, 28, 207-212.	1.5	2
155	Pharmacological Undertreatment of Coronary Risk Factors in Patients with Psoriasis: Observational Study of the Danish Nationwide Registries. PLoS ONE, 2012, 7, e36342.	2.5	48
156	Triterpenoid α-amyrin stimulates proliferation of human keratinocytes but does not protect them against UVB damage Acta Biochimica Polonica, 2012, 59, .	0.5	15
157	Total skin electron beam therapy for cutaneous T-cell lymphoma: A nationwide cohort study from Denmark. Acta Oncológica, 2011, 50, 1199-1205.	1.8	27
158	Atopic Dermatitis-like Pre-Sézary Syndrome: Role of ImmunoÂsupÂpression. Acta Dermato-Venereologica, 2011, 91, 574-577.	1.3	17
159	MicroRNA miR-125b induces senescence in human melanoma cells. Melanoma Research, 2011, 21, 253-256.	1.2	45
160	Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. British Journal of Dermatology, 2011, 164, 1091-1096.	1.5	228
161	Ability to self-detect malignant melanoma decreases with age. Clinical and Experimental Dermatology, 2011, 36, 499-501.	1.3	5
162	Responses to ustekinumab in the antiâ€TNF agentâ€naÃ⁻ve vs. antiâ€TNF agentâ€exposed patients with psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1037-1040.	2.4	62

#	Article	IF	CITATIONS
163	Efficacy and safety of adalimumab in patients with psoriasis previously treated with antiâ€ŧumour necrosis factor agents: subanalysis of BELIEVE. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1012-1020.	2.4	47
164	The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c. Experimental Dermatology, 2011, 20, 278-280.	2.9	23
165	Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood, 2011, 118, 5891-5900.	1.4	237
166	Epidermolysis bullosa acquisita: current diagnosis and therapy. Dermatology Reports, 2011, 3, e38.	0.8	19
167	Are All Melanomas Dangerous?. Acta Dermato-Venereologica, 2011, 91, 499-503.	1.3	23
168	Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 837-839.	2.4	23
169	Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Research, 2010, 20, 479-484.	1.2	75
170	Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood, 2010, 116, 2504-2512.	1.4	78
171	Changes in oncomiR expression in CTCL cell lines during apoptosis induced by Notch inhibition. Leukemia Research, 2010, 34, e235-e236.	0.8	8
172	Programmed cell deathâ€10 enhances proliferation and protects malignant T cells from apoptosis. Apmis, 2010, 118, 719-728.	2.0	42
173	Reproducible pattern of microRNA in normal human skin. Experimental Dermatology, 2010, 19, e201-5.	2.9	20
174	Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach?. British Journal of Dermatology, 2010, 163, 781-788.	1.5	18
175	Growth dynamics and cyclin expression in cutaneous T-cell lymphoma cell lines. Dermatology Reports, 2010, 2, e8.	0.8	5
176	Inhibition of Akt Signaling by Exclusion from Lipid Rafts in Normal and Transformed Epidermal Keratinocytes. Journal of Investigative Dermatology, 2010, 130, 1136-1145.	0.7	72
177	Topical Nutlin-3 Potentiates the UVB-induced p53 Response and Reduces DNA Photodamage and Apoptosis in Mouse Epidermal Keratinocytes in Vivo. Journal of Clinical & Experimental Dermatology Research, 2010, 01, .	0.1	4
178	Systemic Chemotherapy of Non-Melanoma Skin Cancer. , 2010, , 83-90.		0
179	MicroRNA Expression in Melanocytic Nevi: The Usefulness of Formalin-Fixed, Paraffin-Embedded Material for miRNA Microarray Profiling. Journal of Investigative Dermatology, 2009, 129, 1219-1224.	0.7	79
180	Analysis of Extracutaneous Spread in Mycosis Fungoides. Journal of Investigative Dermatology, 2009, 129, 2905-2907.	0.7	2

#	Article	IF	CITATIONS
181	Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis. Experimental Dermatology, 2009, 18, 764-770.	2.9	124
182	Spectrophotometric intracutaneous analysis versus dermoscopy for the diagnosis of pigmented skin lesions: prospective, double-blind study in a secondary reference centre. Melanoma Research, 2009, 19, 176-179.	1.2	35
183	Editorial: Lipid Rafts in Keratinocyte Biology and Pathology. Open Dermatology Journal, 2009, 3, 140-140.	0.3	0
184	Internalization of EGF receptor following lipid rafts disruption in keratinocytes is delayed and dependent on p38 MAPK activation. Journal of Cellular Physiology, 2008, 217, 834-845.	4.1	40
185	A Prospective, Open-Label Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1204-1207.	0.8	37
186	Infliximab inhibits DNA repair in ultraviolet Bâ€irradiated premalignant keratinocytes. Experimental Dermatology, 2008, 17, 933-938.	2.9	15
187	TNFâ€Î± stimulates Akt by a distinct aPKCâ€dependent pathway in premalignant keratinocytes. Experimental Dermatology, 2008, 17, 992-997.	2.9	39
188	TNF-α Impairs the S-G2/M Cell Cycle Checkpoint and Cyclobutane Pyrimidine Dimer Repair in Premalignant Skin Cells: Role of the PI3K–Akt Pathway. Journal of Investigative Dermatology, 2008, 128, 2069-2077.	0.7	25
189	Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia, 2008, 22, 2230-2239.	7.2	82
190	Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30-positive lymphoproliferative disorders. British Journal of Dermatology, 2008, 158, 747-753.	1.5	32
191	Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. International Journal of Dermatology, 2008, 47, 292-294.	1.0	39
192	FOXP3 positive regulatory Tâ€cells in cutaneous and systemic CD30 positive Tâ€cell lymphoproliferations. European Journal of Haematology, 2008, 80, 483-489.	2.2	25
193	Line tension at lipid phase boundaries regulates formation of membrane vesicles in living cells. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 2480-2486.	2.6	37
194	Focal junctions retard lateral movement and disrupt fluid phase connectivity in the plasma membrane. Biochemical and Biophysical Research Communications, 2008, 365, 1-7.	2.1	6
195	Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus. Dermatology, 2008, 217, 268-275.	2.1	33
196	Epidermal Stem Cells - Role in Normal, Wounded and Pathological Psoriatic and Cancer Skin. Current Stem Cell Research and Therapy, 2008, 3, 146-150.	1.3	19
197	Factors Affecting the Recurrence Rate of Basal Cell Carcinoma. Acta Dermato-Venereologica, 2007, 87, 330-334.	1.3	49
198	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood, 2007, 109, 4655-4662.	1.4	200

#	Article	IF	CITATIONS
199	Maintenance therapy in cutaneous T-cell lymphoma: Who, when, what?. European Journal of Cancer, 2007, 43, 2321-2329.	2.8	56
200	The optimal use of bexarotene in cutaneous T-cell lymphoma. British Journal of Dermatology, 2007, 157, 433-440.	1.5	150
201	Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/lgG1 fusion protein alefacept. Clinical and Experimental Immunology, 2007, 149, 23-30.	2.6	21
202	Putative cancer stem cells in cutaneous malignancies. Experimental Dermatology, 2007, 16, 297-301.	2.9	42
203	The autocrine TNFα signalling loop in keratinocytes requires atypical PKC species and NF-κB activation but is independent of cholesterol-enriched membrane microdomains. Biochemical Pharmacology, 2007, 73, 526-533.	4.4	18
204	Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just â€~̃witnesses of disease'?. Experimental Dermatology, 2006, 15, 815-815.	2.9	95
205	Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. British Journal of Dermatology, 2006, 155, 261-266.	1.5	108
206	Ligand-Independent Activation of the EGFR by Lipid Raft Disruption. Journal of Investigative Dermatology, 2006, 126, 954-962.	0.7	86
207	In Vitro Techniques. , 2006, , 201-378.		2
208	Severe Exacerbation of Psoriatic Arthritis during Treatment with Efalizumab. A Case Report. Acta Dermato-Venereologica, 2006, 86, 456-457.	1.3	13
209	Desmoglein autoimmunity in the pathogenesis of pemphigus. Autoimmunity, 2006, 39, 541-547.	2.6	18
210	Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just â€~witnesses of disease'?. Experimental Dermatology, 2006, 15, 815-831.	2.9	34
211	UV-induced DNA damage in human keratinocytes: Quantitation and correlation with long-term survival. Experimental Dermatology, 2005, 14, 349-355.	2.9	52
212	Disruption of lipid rafts causes apoptotic cell death in HaCaT keratinocytes. Experimental Dermatology, 2005, 14, 266-272.	2.9	57
213	Infectious Urticaria with Purpura: A Mild Subtype of Urticarial Vasculitis?. Acta Dermato-Venereologica, 2005, 85, 167-170.	1.3	7
214	Do Neoplastic Stem Cells Underlie the Pathogenesis of Cutaneous Lymphomas?. Archives of Dermatology, 2005, 141, 641.	1.4	5
215	Do Neoplastic Stem Cells Underlie the Pathogenesis of Cutaneous Lymphomas?—Reply. Archives of Dermatology, 2005, 141, .	1.4	1
216	Monoclonal T-Cell Dyscrasia of Undetermined Significance Associated With Recalcitrant Erythroderma. Archives of Dermatology, 2005, 141, 361-367.	1.4	41

#	Article	IF	CITATIONS
217	Neoplastic Stem Cells in Cutaneous Lymphomas. Archives of Dermatology, 2004, 140, 1156-60.	1.4	19
218	CD56+ Lymphoma With Skin Involvement. Archives of Dermatology, 2004, 140, 427-36.	1.4	27
219	Lipid raft-enriched stem cell-like keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa. Experimental Dermatology, 2004, 13, 361-363.	2.9	34
220	Melanoma Diagnosis by Raman Spectroscopy and Neural Networks: Structure Alterations in Proteins and Lipids in Intact Cancer Tissue. Journal of Investigative Dermatology, 2004, 122, 443-449.	0.7	286
221	Skin aging and natural photoprotection. Micron, 2004, 35, 185-191.	2.2	189
222	Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochemical and Biophysical Research Communications, 2004, 320, 165-169.	2.1	114
223	Dihydroxyacetone, the active browning ingredient in sunless tanning lotions, induces DNA damage, cell-cycle block and apoptosis in cultured HaCaT keratinocytes. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2004, 560, 173-186.	1.7	64
224	Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Dermato-Venereologica, 2004, 84, 247-8.	1.3	8
225	Intracellular calcium pool emptying induces DNA synthesis in HaCaT keratinocytes. Experimental Dermatology, 2003, 12, 453-459.	2.9	11
226	Flotillas of Lipid Rafts in Transit Amplifying Cell-Like Keratinocytes. Journal of Investigative Dermatology, 2003, 121, 522-528.	0.7	24
227	Expression of T-cell activation marker CD134 (OX40) in lymphomatoid papulosis. British Journal of Dermatology, 2003, 148, 885-891.	1.5	15
228	In vivo UVB irradiation induces clustering of Fas (CD95) on human epidermal cells. Experimental Dermatology, 2003, 12, 791-798.	2.9	347
229	Bone marrow precursor of extranodal T-cell lymphoma. Blood, 2003, 102, 3797-3799.	1.4	40
230	Deletion of Deoxyribonucleic Acid Binding Domain of the Vitamin D Receptor Abrogates Genomic and Nongenomic Functions of Vitamin D. Molecular Endocrinology, 2002, 16, 1524-1537.	3.7	267
231	IgA Pemphigus: The First Two Scandinavian Cases. Acta Dermato-Venereologica, 2002, 82, 441-445.	1.3	12
232	Trends and Developments in the Pharmacological Treatment of Psoriasis. Acta Dermato-Venereologica, 2002, 82, 401-410.	1.3	10
233	Emerging drugs in psoriasis. Expert Opinion on Emerging Drugs, 2002, 7, 69-90.	2.4	11
234	Phototoxicity to diuretics and antidiabetics in the cultured keratinocyte cell line HaCaT: evaluation Photoimmunology and Photomedicine, 2002, 18, 90-95.	1.5	24

#	Article	IF	CITATIONS
235	Calcipotriol for erythema annulare centrifugum. British Journal of Dermatology, 2002, 146, 317-319.	1.5	29
236	Cholesterol-Rich Plasma Membrane Domains (Lipid Rafts) in Keratinocytes: Importance in the Baseline and UVA-Induced Generation of Reactive Oxygen Species. Journal of Investigative Dermatology, 2002, 118, 582-588.	0.7	59
237	Deletion of Deoxyribonucleic Acid Binding Domain of the Vitamin D Receptor Abrogates Genomic and Nongenomic Functions of Vitamin D. Molecular Endocrinology, 2002, 16, 1524-1537.	3.7	69
238	Changes in the ultrastructure of cytoskeleton and nuclear matrix during HaCaT keratinocyte differentiation. Experimental Dermatology, 2001, 10, 71-79.	2.9	16
239	Role of mitochondria in ultraviolet-induced oxidative stress. Journal of Cellular Biochemistry, 2001, 80, 216-222.	2.6	106
240	Differences in activation of G2/M checkpoint in keratinocytes after genotoxic stress induced by hydrogen peroxide and ultraviolet a radiation. Free Radical Research, 2001, 35, 405-416.	3.3	30
241	Antidiabetics and diuretics show phototoxicity in HaCaT cells. , 2001, , .		0
242	Laser scanning cytometry for comet assay analysis. , 2000, 39, 10-15.		24
243	STRUCTURAL ASSOCIATION OF BAX WITH NUCLEAR MATRIX AND CYTOMATRIX REVEALED BY EMBEDMENT-FREE IMMUNOGOLD ELECTRON MICROSCOPY. Cell Biology International, 2000, 24, 649-656.	3.0	14
244	Lack of Membrane Expression of Interleukin-2 Receptor α Chain (CD25) in Mycosis Fungoides: Application of Laser Scanning Cytometry for Phenotyping of Skin Infiltrating Lymphocytes. Journal of Investigative Dermatology, 2000, 114, 594-595.	0.7	3
245	Hydrogen peroxide is responsible for UVA-induced DNA damage measured by alkaline comet assay in HaCaT keratinocytes. Journal of Photochemistry and Photobiology B: Biology, 2000, 59, 123-131.	3.8	122
246	Rigid Definitions Restrict the Evolution of Understanding. Archives of Dermatology, 2000, 136, 1271-1271.	1.4	1
247	Constitutive Speckled Vascular Mottling of the Skin Resembling Bier White Spots: Lack of Venoarteriolar Reflex in Dermal Arterioles. Archives of Dermatology, 2000, 136, 674-a-675.	1.4	24
248	Resistance of senescent keratinocytes to UV-induced apoptosis. Cellular and Molecular Biology, 2000, 46, 121-7.	0.9	7
249	Structure of cytomatrix and nuclear matrix revealed by embedment-free electron microscopy. Acta Neurobiologiae Experimentalis, 2000, 60, 147-58.	0.7	3
250	Emerging drugs in psoriasis. Expert Opinion on Emerging Drugs, 1999, 4, 309-332.	1.1	1
251	Induction of endothelial nitric oxide synthase in perivascular mast cells in rat neurohypophysis after ischemia. Neuroendocrinology Letters, 1999, 20, 189-193.	0.2	1
252	Evidence for the Activation of Vitamin D Compounds in the Skin by Side–Chain Hydroxylation. Basic and Clinical Pharmacology and Toxicology, 1998, 82, 173-176.	0.0	3

ROBERT GNIADECKI

#	Article	IF	CITATIONS
253	Nongenomic signaling by vitamin D. Biochemical Pharmacology, 1998, 56, 1273-1277.	4.4	43
254	Regulation of Keratinocyte Proliferation. General Pharmacology, 1998, 30, 619-622.	0.7	47
255	Resistance of senescent keratinocytes to UV-induced apoptosis. Journal of the European Academy of Dermatology and Venereology, 1998, 11, S169.	2.4	1
256	Relationship between keratinocyte adhesion and death: anoikis in acantholytic diseases. Archives of Dermatological Research, 1998, 290, 528-532.	1.9	82
257	Involvement of Src in the vitamin D signaling in human keratinocytes. Biochemical Pharmacology, 1998, 55, 499-503.	4.4	24
258	Disruption of the Vertical Calcium Gradient in Murine Epidermis by a Potent Vitamin D3 Analogue, KH 1060. Acta Dermato-Venereologica, 1998, 78, 164-168.	1.3	4
259	Variable Expression of Apoptotic Phenotype in Keratinocytes Treated with Ultraviolet Radiation, Ceramide, or Suspended in Semisolid Methylcellulose. Acta Dermato-Venereologica, 1998, 78, 248-257.	1.3	14
260	1,25-Dihydroxyvitamin D3 Stimulates the Assembly of Adherens Junctions in Keratinocytes: Involvement of Protein Kinase C. Endocrinology, 1997, 138, 2241-2248.	2.8	71
261	Two Pathways for Induction of Apoptosis by Ultraviolet Radiation in Cultured Human Keratinocytes. Journal of Investigative Dermatology, 1997, 109, 163-169.	0.7	87
262	Effects of 1,25-dihydroxyvitamin D3 and its 20-epi analogues (MC 1288, MC 1301, KH 1060), on clonal keratinocyte growth: evidence for differentiation of keratinocyte stem cells and analysis of the modulatory effects of cytokines. British Journal of Pharmacology, 1997, 120, 1119-1127.	5.4	23
263	1,25-Dihydroxyvitamin D3 Stimulates the Assembly of Adherens Junctions in Keratinocytes: Involvement of Protein Kinase C. Endocrinology, 1997, 138, 2241-2248.	2.8	9
264	Impairment of granulation tissue formation after menopause. Journal of Endocrinological Investigation, 1996, 19, 215-218.	3.3	6
265	Stimulation versus Inhibition of Keratinocyte Growth by 1,25-Dihydroxyvitamin D3: Dependence on Cell Culture Conditions. Journal of Investigative Dermatology, 1996, 106, 510-516.	0.7	105
266	Activation of Raf—Mitogen–Activated Protein Kinase Signaling Pathway by 1,25-Dihydroxyvitamin D3 in Normal Human Keratinocytes. Journal of Investigative Dermatology, 1996, 106, 1212-1217.	0.7	86
267	Stimulation of epidermal proliferation in mice with 1α,25-dihydroxyvitamin D3 and receptor-active 20-epi analogues of 1α,25-dihydroxyvitamin D3. Biochemical Pharmacology, 1995, 49, 621-624.	4.4	48
268	The effects of KH 1060, a potent 20-epi analogue of the vitamin D3 hormone, on hairless mouse skin in vivo. British Journal of Dermatology, 1995, 132, 841-852.	1.5	18
269	Pathogenesis is multifactorial. BMJ: British Medical Journal, 1995, 311, 749-750.	2.3	2
270	Ultrastructure of murine epidermis treated with the vitamin D3 analogue KH-1060 Acta Dermato-Venereologica, 1995, 75, 222-227.	1.3	0

#	Article	IF	CITATIONS
271	Enhancement of the granulation tissue formation in hairless mice by a potent vitamin D receptor agonist – KH 1060. Journal of Endocrinology, 1994, 141, 411-415.	2.6	1
272	Inhibition of glucocorticoidâ€induced epidermal and dermal atrophy with KH 1060 – a potent 20â€epi analogue of 1,25â€dihydroxyvitamin D ₃ . British Journal of Pharmacology, 1994, 113, 439-444.	5.4	12
273	Ultrasound Structure and Digital Image Analysis of the Subepidermal Low Echogenic Band in Aged Human Skin: Diurnal Changes and Interindividual Variability. Journal of Investigative Dermatology, 1994, 102, 362-365.	0.7	112
274	A vitamin D analogue KH 1060 activates the protein kinase C– c-fos signalling pathway to stimulate epidermal proliferation in murine skin. Journal of Endocrinology, 1994, 143, 521-525.	2.6	13
275	Changes in skin disaccharide components correlate with the severity of sclerotic skin in systemic sclerosis Acta Dermato-Venereologica, 1994, 74, 179-182.	1.3	9
276	Skin mechanical properties present adaptation to man's upright position. In vivo studies of young and aged individuals Acta Dermato-Venereologica, 1994, 74, 188-190.	1.3	18
277	Microvascular reactions to postural changes in patients with sickle cell anaemia Acta Dermato-Venereologica, 1994, 74, 191-193.	1.3	6
278	Alterations of skin microcirculatory rhythmic oscillations in different positions of the lower extremity. Acta Dermato-Venereologica, 1992, 72, 259-60.	1.3	1
279	The effect of limb oedema and compressive bandaging on postural vasoconstriction in humans. Archives of Dermatological Research, 1991, 283, 485-486.	1.9	3
280	THE INFLUENCE OF PRETRANSPLANT AND POSTTRANSPLANT IMMUNOSUPPRESSION ON CARDIAC GRAFT SURVIVAL IN THE DONOR-SPECIFIC TRANSFUSION MODEL IN MICE. Transplantation, 1989, 47, 913-914.	1.0	9
281	Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER). SKIN the Journal of Cutaneous Medicine, O. 1, s128	0.3	0